Endocrine Abstracts

Background: Orolactin-producing tumours are the most frequent pituitary tumours, representing 40% of these tumours, with an annual incidence of 6–10 cases/million. <10% are macroprolactinomas, which vary by age and gender, with female to male ratio of 10:1, however, less diagnosed in this population group.

Objective: To describe clinical features and therapeutic response of 30 women with invasive macroprolactinoma.

Methods: Follow a cohort of 30 patients was performed, aged 18–47 years, in Imbanaco Endocrine Clinic Medical Center in Cali, Colombia, between 2002 and 2012. Demographic and clinical characteristics were analysed; signs, symptoms, hormone levels, surgery and complications. Univariate analysis to estimate proportions and measures of central tendency was performed according to the nature of the variable. Treatment success was defined as a decrease in time macroprolactinomas size, measured by NMR and decrease in serial serum prolactin. Parametric tests were used to compare serum prolactin and tumor size Fisher Snedecor’s F was applied.

Results: The mean age was 35 years, and BMI 28. The symptoms were; 96.7% headache, menstrual disorders, 90, 80% hipopituarismo, visual disorder 76.7% decreased libido 73.3% Galactorrhoea/asthenia 70%, infertility 60, 30% unilateral amaurosis. Trans-cranial 16.7, 43.3% trans-sphenoidal surgery, 23% of patients started with bromocriptine, of these 10% used it as monotherapy, 13% remaining, cabergoline should start. 86% received only cabergoline. Regarding complications presented 20% empty sella, 3.3% rinoliquia. With statistically significant differences (P<0.0001) measurements at 6 and 12 months in the three diameters relative to the benchmark, like serum prolactin.

Conclusion: Interventions Patients were successful in 100% of cases.